[COMPANY LOGO]
CONTACT:
- --------
Kara Stancell, Investor Relations & Corporate Communications, (602) 808-3854
MEDICIS REPORTS THIRD QUARTER FISCAL 2004 FINANCIAL RESULTS
SCOTTSDALE, Arizona--April 29, 2004--Medicis (NYSE:MRX) today announced third
quarter fiscal 2004 revenues of $81.8 million with "if-converted" net income of
$21.5 million, or $0.33 per diluted share, compared to third quarter fiscal 2003
revenues of $62.6 million with net income of $15.8 million, or $0.28 per diluted
share, absent a $5.5 million tax-effected special charge reported in third
quarter fiscal 2003 associated with a research and development collaboration.
Including the tax-effected special charge of $5.5 million, the Company reported
Generally Accepted Accounting Principles ("GAAP") net income of $10.2 million,
or $0.18 per diluted share for the third quarter of fiscal 2003. Third quarter
fiscal 2004 diluted per share amounts are calculated using the "if-converted"
method of accounting in accordance with GAAP due to the outstanding 2.5%
Convertible Senior Notes meeting the criteria for conversion, regardless of
whether the bondholders actually convert their bonds into shares. Third quarter
fiscal 2003 diluted per share amounts do not reflect the "if-converted" method,
as the criteria for conversion had not been met.
Third quarter fiscal 2004 revenues increased approximately 31% primarily as a
result of net overall growth in sales of the Company's core brands, including
both U.S. and Canadian sales of RESTYLANE(R). At the end of the third quarter,
the Company's core brands included DYNACIN(R), LOPROX(R), OMNICEF(R),
ORAPRED(R), PLEXION(R), RESTYLANE(R) and TRIAZ(R). These core brands represented
approximately 87% of total product sales. Prescription volume growth for the
Company's core brands, excluding RESTYLANE(R), increased 12% in both new and
total prescriptions. The Company's gross profit margin was 84% for the third
quarter fiscal 2004.
For the nine months ended March 31, 2004, Medicis reported revenues of $215.8
million with "if-converted" net income of $48.7 million, or $0.76 per diluted
share, absent a $37.5 million tax-effected loss associated with the early
extinguishment of debt reported in the first nine months of fiscal 2004 and
absent a $1.6 million tax-effected special charge associated with a research and
development collaboration reported in the first nine months of fiscal 2004.
Including the tax-effected special charges of $37.5 million and $1.6 million in
the nine months ended March 31, 2004, Medicis reported a GAAP net income of $7.1
million, or $0.12 per diluted share for the first nine months of fiscal 2004.
Comparatively, in the first nine months of fiscal 2003, Medicis reported
revenues of $180.8 million with net income of $46.4 million, or $0.82 per
diluted share, absent an $8.9 million tax-effected special charge reported in
the first nine months of fiscal 2003 associated with a research and development
collaboration. Including the tax-effected special charge of $8.9 million,
Medicis reported GAAP net income of $37.4 million, or $0.66 per diluted share
for the first nine months of fiscal 2003. For the first nine months of fiscal
2004, diluted per share amounts (absent special charges) are calculated using
the "if-converted" method of accounting in accordance with GAAP. For the nine
months ended March 31, 2004, the dilutive shares relative to the convertible
notes do not impact GAAP earnings per share, as they are anti-dilutive. For the
first nine months of fiscal 2003, diluted per share amounts do not reflect the
"if-converted" method, as the criteria for conversion had not been met.
For the first nine months of fiscal 2004, revenue increased approximately 19%
primarily as a result of net overall growth in sales of the Company's core
brands, including both U.S. and Canadian sales of
(more)
RESTYLANE(R). In the first nine months of fiscal 2004, the Company's core brands
represented approximately 87% of total product sales. Prescription volume growth
for the Company's core brands, excluding RESTYLANE(R), increased 18% in new
prescriptions and 15% in total prescriptions. The Company's gross profit margin
for the nine months ended March 31, 2004 was 84%.
Selling, general and administrative expenses in third quarter fiscal 2004
increased approximately 21% to $28.8 million, as the Company incurred
incremental costs associated with the product launch and first U.S. commercial
sales of RESTYLANE(R), which began on January 6, 2004. The Company has incurred
incremental costs associated with the product launch, including the hiring of a
dedicated aesthetics sales force, additional headquarters personnel to support
sales force efforts, including product management, customer service and training
personnel, expenses associated with public relations, physician training and
continuing medical education, and other administrative expenses.
"We are pleased to announce a very solid quarter led by the U.S. launch of
RESTYLANE(R)," said Jonah Shacknai, Chairman and Chief Executive Officer of
Medicis. "RESTYLANE(R) quickly is becoming the preferred dermal filler among
physicians and patients in the aesthetics marketplace. As a result of the strong
launch of RESTYLANE(R), the Company continues to expand its sales growth rate,
operating margins and net income margins. With the launch of innovative products
such as RESTYLANE(R), Medicis intends to maintain leadership in the fields of
dermatology and aesthetics medicine."
Medicis previously released updated fiscal 2004 revenue guidance of
approximately $292 million and earnings per share guidance of $1.09. The Company
is raising its previous fiscal 2004 revenue guidance by $8 million to
approximately $300 million, and earnings per share guidance by $0.03 to $1.12,
excluding special charges. Based upon information available currently to the
Company, its guidance is as follows:
Fiscal Year 2004
ending June 30, 2004
(in millions, except per share amounts)
First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year
(9/30/03) (12/31/03) (3/31/04) (6/30/04) 2004
Actual Actual Actual Estimated Estimated
------------ ------------ ---------- ------------ ----------
Current revenue
objectives $63 $71 $82 $84 $300
Previous EPS guidance
reflective of stock split* $0.18 $0.24 $0.31 $0.35 $1.09
Current EPS objectives
reflective of stock split* $0.18 $0.25 $0.33 $0.36 $1.12
*Excluding tax-effected loss on early extinguishment of debt, special charges
relating to research and development collaborations and including the
application of the "if-converted" method in accordance with GAAP
At the time of this disclosure, Medicis believes these objectives are attainable
based upon information currently available to the Company. The Company's
business is subject to all risk factors outlined in the Company's most recent
annual report on Form 10-K, its Form S-3 registration statement and other filed
documents with the Securities and Exchange Commission. At the time of this
release, the Company cannot, among other things, assess the forthcoming results
of the Company's research and development projects and the risks associated with
the FDA approval process, risks associated with significant competition within
the Company's industry, nor can the Company validate its assumptions of the full
impact on its business of the approval of competitive generic versions of the
Company's core brands, or any future competitive product approvals that may
affect the Company's brands. Additionally, Medicis may acquire and/or license
products or technologies from third parties to enter into new strategic markets.
The Company periodically makes up-front, non-refundable payments to third
parties for research and development work which has been
(more)
completed and periodically makes additional non-refundable payments for the
achievement of various milestones. There can be no certainty which periods these
potential payments could be made, nor if any payments such as these will be made
at all. The above estimated future guidance does not include the potential
payments associated with any such transactions.
Medicis is the leading independent specialty pharmaceutical company in the
United States focusing primarily on the treatment of dermatological and
podiatric conditions and aesthetics medicine. Medicis has leading branded
prescription products in a number of therapeutic categories, including acne,
eczema, fungal infections, hyperpigmentation, photoaging, psoriasis, rosacea,
seborrheic dermatitis and skin and skin-structure infections. The Company's
products have earned wide acceptance by both physicians and patients due to
their clinical effectiveness, high quality and cosmetic elegance.
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R)
(minocycline HCl), LOPROX(R) (ciclopirox), LUSTRA(R) (hydroquinone),
LUSTRA-AF(R) (hydroquinone) with sunscreen, ALUSTRA(R) (hydroquinone) with
retinol, OMNICEF(R) (cefdinir), ORAPRED(R) (prednisolone sodium phosphate),
PLEXION(R) Cleanser (sodium sulfacetamide/sulfur), PLEXION TS(R) (sodium
sulfacetamide/sulfur), PLEXION SCT(R) (sodium sulfacetamide/sulfur), TRIAZ(R)
(benzoyl peroxide), LIDEX(R) (fluocinonide), and SYNALAR(R) (fluocinolone
acetonide), the over-the-counter brand ESOTERICA(R), and BUPHENYL(R) (sodium
phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle
Disorder. For more information about Medicis, please visit the Company's website
at www.medicis.com.
Except for historical information, this press release includes "forward-looking
statements" within the meaning of the Securities Litigation Reform Act. All
statements included in this press release that address activities, events or
developments that Medicis expects, believes or anticipates will or may occur in
the future are forward-looking statements. This includes earnings estimates,
future financial performance and other matters. These statements are based on
certain assumptions made by Medicis based on its experience and perception of
historical trends, current conditions, expected future developments and other
factors it believes are appropriate in the circumstances. Such statements are
subject to a number of assumptions, risks and uncertainties, many of which are
beyond the control of Medicis. Any such projections or statements include the
current views of Medicis with respect to future events and financial
performance. No assurances can be given, however, that these events will occur
or that such results will be achieved. Medicis cannot validate its assumptions
of the full impact on its business of the approval of competitive generic
versions of its core brands, or any future competitive product approvals that
may affect its brands. Also, there are a number of additional important factors
that could cause actual results to differ materially from those projected,
including the anticipated size of the markets, the availability of product
supply, the receipt of required regulatory approvals, the ability to realize
anticipated synergies and benefits of the Q-Med transaction, the risks and
uncertainties normally incident to the pharmaceutical industry, dependence on
sales of key products, the uncertainty of future financial results and
fluctuations in operating results, dependence on Medicis' strategy including the
uncertainty of license payments and/or other payments due from third parties,
the timing and success of new product development by Medicis or third parties,
product introductions and other risks described from time to time in Medicis'
SEC filings including its Annual Report on Form 10-K for the year ended June 30,
2003. There can be no assurance as to when or if any of the holders of the Notes
will have the right to convert or if the Notes will be converted, and what
impact the increase in the number of shares outstanding will have on its results
of operations. Forward-looking statements represent the judgment of Medicis'
management as of the date of this release, and Medicis disclaims any intent or
obligation to update any forward-looking statements.
NOTE: Full prescribing information for any Medicis prescription product is
available by contacting the Company. OMNICEF(R) is a registered trademark of
Abbott Laboratories, Inc. under a license from Fujisawa Pharmaceutical Co., Ltd.
ORAPRED(R) is a registered trademark of Ascent Pediatrics, Inc., a wholly owned
subsidiary of Medicis Pharmaceutical Corporation. RESTYLANE(R) is a registered
trademark of HA North American Sales AB, a subsidiary of Medicis Pharmaceutical
Corporation. All other marks (or brands) and names are the property of Medicis
or its Affiliates.
(more)
Medicis
Summary Statements of Operations
--------------------------------
(in thousands, except per share data)
(unaudited)
Three Months Ended Nine Months Ended
March 31, March 31,
----------------------------------- -----------------------------------
2004 2003 2004 2003
----------------------------------- -----------------------------------
Revenues $ 81,839 $ 62,575 $ 215,767 $ 180,834
Cost of sales 13,118 9,114 34,537 27,579
-------- -------- -------- --------
Gross profit 68,721 53,461 181,230 153,255
Operating expenses:
Selling, general and administrative 28,793 23,809 87,907 67,739
Research and development 3,084 11,189* 12,375** 21,352*
Depreciation and amortization 4,707 2,572 11,872 6,747
Loss on early extinguishment of debt ---- ---- 58,660 ----
-------- -------- -------- --------
Total operating expenses 36,584 37,570 170,814 95,838
Operating income 32,137 15,891 10,416 57,417
Interest income (expense), net (335) (161) (449) 129
Income tax expense (11,131) (5,506) (2,832) (20,141)
-------- -------- -------- --------
Net income $ 20,671 $ 10,224 $ 7,135 $ 37,405
======== ======== ====== =========
Basic net income per common share $0.37 $0.19 $0.13 $0.69
===== ===== ===== =====
Diluted net income per common share $0.33*** $0.18 $0.12*** $0.66
===== ===== ===== =====
Shares used in basic net income per common share 56,042 54,168 55,198 54,388
Shares used in diluted net income per common share 65,839 56,237 58,569 56,272
Cash flow from operations $ 37,446 $ 26,846 $ 77,428 $ 68,632
- ------------------------------------------------------------------------------------------------------------------------------------
GAAP Net income $ 20,671 $ 10,224 $ 7,135 $ 37,405
Interest expense and associated bond offering
costs (tax-effected) 836*** ---- 2,508*** ----
Special charge for R&D (tax-effected) ---- 5,544 1,575 8,946
Loss on early extinguishment of debt (tax-effected) ---- ---- 37,474 ----
-------- -------- -------- --------
"If-converted" net income prior to special charge and
loss on early extinguishment of debt $ 21,507 $ 15,768 $ 48,692 $ 46,351
======== ======== ========= =========
Shares used in diluted net income per common
share 65,839 56,237 64,392 56,272
Diluted net income per common share $0.33 $0.28 $0.82 $0.76
===== ===== ===== =====
- ------------------------------------------------------------------------------------------------------------------------------------
*Reported R&D expenses include a special charge of $8.8 million ($5.5 million
tax-effected) in the third quarter of fiscal 2003 and $14.2 million ($8.9
million tax-effected) in the first nine months of fiscal 2003 relating to a
research & development collaboration
**Reported R&D expenses include a special charge of $2.4 million ($1.6 million
tax-effected) in the first nine months of fiscal 2004 relating to a research &
development collaboration
***To calculate diluted earnings per share, tax-effected net interest on the
2.5% contingent convertible notes and associated bond offering costs of $836,000
is added back to GAAP net income for the three months ended March 31, 2004, and
divided by shares used in diluted net income per common share. For the nine
months ended March 31, 2004, the dilutive shares relative to the convertible
notes do not impact earnings per share, as they are anti-dilutive.
Balance Sheets
--------------
At March 31, 2004 At June 30, 2003
----------------- ----------------
(unaudited)
Assets
Cash, cash equivalents & short-term investments $588,746 $552,663
Accounts receivable, net 49,902 51,661
Inventory, net 19,609 14,005
Other current assets 39,488 27,299
------ ------
Total current assets 697,745 645,628
Property and equipment, net 5,596 3,094
Intangible assets, net 327,513 278,269
Other assets 7,825 9,999
----- -----
Total assets $1,038,679 $936,990
========== ========
Liabilities and stockholders' equity
Current liabilities $ 69,520 $ 68,847
Contingent convertible senior notes 2.5% due 2032 169,157 400,000
Contingent convertible senior notes 1.5% due 2033 283,910 ---
Deferred tax liability 460 7,022
Stockholders' equity 515,632 461,121
- ------- -------
Total liabilities and stockholders' equity $1,038,679 $936,990
========== ========
Working capital $628,225 $576,781
======== ========
# # #